- Home
- SBSI vs OCS Comparison
SBSI vs OCS Comparison
Compare SBSI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBSI
- OCS
- Stock Information
- Founded
- SBSI 1960
- OCS 2003
- Country
- SBSI United States
- OCS Switzerland
- Employees
- SBSI N/A
- OCS N/A
- Industry
- SBSI Major Banks
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- SBSI Finance
- OCS Health Care
- Exchange
- SBSI Nasdaq
- OCS Nasdaq
- Market Cap
- SBSI 920.2M
- OCS 956.4M
- IPO Year
- SBSI N/A
- OCS N/A
- Fundamental
- Price
- SBSI $30.43
- OCS $17.09
- Analyst Decision
- SBSI Hold
- OCS Strong Buy
- Analyst Count
- SBSI 3
- OCS 4
- Target Price
- SBSI $35.00
- OCS $35.75
- AVG Volume (30 Days)
- SBSI 103.4K
- OCS 13.4K
- Earning Date
- SBSI 10-23-2025
- OCS 11-06-2025
- Dividend Yield
- SBSI 4.73%
- OCS N/A
- EPS Growth
- SBSI 4.30
- OCS N/A
- EPS
- SBSI 2.81
- OCS N/A
- Revenue
- SBSI $254,956,000.00
- OCS $960,668.00
- Revenue This Year
- SBSI $11.17
- OCS $11.49
- Revenue Next Year
- SBSI $5.65
- OCS $1,784.02
- P/E Ratio
- SBSI $10.84
- OCS N/A
- Revenue Growth
- SBSI 6.01
- OCS N/A
- 52 Week Low
- SBSI $25.85
- OCS $11.78
- 52 Week High
- SBSI $38.00
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- SBSI 48.44
- OCS 44.25
- Support Level
- SBSI $30.30
- OCS $16.00
- Resistance Level
- SBSI $30.81
- OCS $17.35
- Average True Range (ATR)
- SBSI 0.48
- OCS 0.39
- MACD
- SBSI -0.09
- OCS 0.06
- Stochastic Oscillator
- SBSI 7.72
- OCS 51.67
About SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.